IMJUDO tremelimumab 300 mg/ 15 mL concentrated injection vial

Krajina: Austrália

Jazyk: angličtina

Zdroj: Department of Health (Therapeutic Goods Administration)

Aktívna zložka:

tremelimumab, Quantity: 300 mg

Dostupné z:

AstraZeneca Pty Ltd

Forma lieku:

Injection, concentrated

Zloženie:

Excipient Ingredients: histidine hydrochloride monohydrate; disodium edetate; polysorbate 80; water for injections; trehalose dihydrate; histidine

Spôsob podávania:

Intravenous Infusion

Počet v balení:

1 vial

Typ predpisu:

(S4) Prescription Only Medicine

Terapeutické indikácie:

Hepatocellular Carcinoma (HCC),IMJUDO in combination with durvalumab is indicated for the treatment of adult patients with unresectable hepatocellular carcinoma (uHCC) who have not received prior treatment with a PD-1/PD-L1 inhibitor.

Prehľad produktov:

Visual Identification: Clear to slightly opalescent, colourless to slightly yellow solution, free from or practically free from visible particles.; Container Type: Vial; Container Material: Glass Type I Clear; Container Life Time: 48 Months; Container Temperature: Store at 2 to 8 degrees Celsius; Container Closure: Neither child resistant closure nor restricted flow insert

Stav Autorizácia:

Registered

Dátum Autorizácia:

2023-06-23